Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 17/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | RECQL | P46063 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26843370 | 0.87 | TOP1 (0.77) | TOP1KDM4ERECQLTDP1POLB | |
| SCHEMBL17779637 | 0.87 | TOP1 (0.71) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL17779639 | 0.86 | TOP1 (0.76) | TOP1KDM4ERECQLTDP1POLB | |
| 9-Aminocamptothecin SCHEMBL29369669 | 0.84 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1POLB | |
| 9-Aminocamptothecin SCHEMBL26578 | 0.84 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1POLB | |
| Rs-9-Aminocamptothecin SCHEMBL8715088 | 0.84 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1POLB | |
| SCHEMBL25932523 | 0.83 | TOP1 (0.84) | TOP1KDM4ERECQLTDP1POLB | |
| SCHEMBL21841852 | 0.81 | TOP1 (0.75) | TOP1KDM4ERECQLTDP1POLB | |
| Rs-9-Aminocamptothecin SCHEMBL27705522 | 0.81 | TOP1 (0.92) | TOP1KDM4ERECQLTDP1POLB | |
| SCHEMBL20365198 | 0.79 | MEN1 (0.60) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000860-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2022-01-06 | — | — | US | claimed |
| US-11116762-B2 | Compounds, compositions, and methods for treating human immunodeficiency virus | OYAGEN, INC. (US) | 2021-09-14 | — | — | US | claimed |
| US-20190350925-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2019-11-21 | — | — | US | claimed |
| US-20220000860-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220000860-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11116762-B2 | Compounds, compositions, and methods for treating human immunodeficiency virus | OYAGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11116762-B2 | Compounds, compositions, and methods for treating human immunodeficiency virus | OYAGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20190350925-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190350925-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | OYAGEN, INC. (US) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350925-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | HAVCR2, TTPA, CD4 | TOP1 338/4885KDM4E 4100/4885RECQL 276/4885 |
| US-11116762-B2 | Compounds, compositions, and methods for treating human immunodeficiency virus | HAVCR2, TTPA, CD4 | TOP1 338/4885KDM4E 4100/4885RECQL 276/4885 |
| US-20220000860-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS | HAVCR2, TTPA, CD4 | TOP1 338/4885KDM4E 4100/4885RECQL 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.